Your browser doesn't support javascript.
loading
Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation.
Saslow, Debbie; Andrews, Kimberly S; Manassaram-Baptiste, Deana; Smith, Robert A; Fontham, Elizabeth T H.
Afiliación
  • Saslow D; Human Papillomavirus and Gynecologic Cancers, American Cancer Society, Atlanta, Georgia.
  • Andrews KS; Guideline Development Process, American Cancer Society, Atlanta, Georgia.
  • Manassaram-Baptiste D; Guideline Development Process, American Cancer Society, Atlanta, Georgia.
  • Smith RA; Cancer Screening, American Cancer Society, Atlanta, Georgia.
  • Fontham ETH; Louisiana State University School of Public Health, New Orleans, Louisiana.
CA Cancer J Clin ; 70(4): 274-280, 2020 07.
Article en En | MEDLINE | ID: mdl-32639044
The American Cancer Society (ACS) presents an adaptation of the current Advisory Committee on Immunization Practices recommendations for human papillomavirus (HPV) vaccination. The ACS recommends routine HPV vaccination between ages 9 and 12 years to achieve higher on-time vaccination rates, which will lead to increased numbers of cancers prevented. Health care providers are encouraged to start offering the HPV vaccine series at age 9 or 10 years. Catch-up HPV vaccination is recommended for all persons through age 26 years who are not adequately vaccinated. Providers should inform individuals aged 22 to 26 years who have not been previously vaccinated or who have not completed the series that vaccination at older ages is less effective in lowering cancer risk. Catch-up HPV vaccination is not recommended for adults aged older than 26 years. The ACS does not endorse the 2019 Advisory Committee on Immunization Practices recommendation for shared clinical decision making for some adults aged 27 through 45 years who are not adequately vaccinated because of the low effectiveness and low cancer prevention potential of vaccination in this age group, the burden of decision making on patients and clinicians, and the lack of sufficient guidance on the selection of individuals who might benefit.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunación Masiva / Esquemas de Inmunización / Infecciones por Papillomavirus / Vacunas contra Papillomavirus / Neoplasias Tipo de estudio: Guideline / Prognostic_studies / Sysrev_observational_studies Aspecto: Implementation_research Límite: Adolescent / Adult / Child / Female / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: CA Cancer J Clin Año: 2020 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunación Masiva / Esquemas de Inmunización / Infecciones por Papillomavirus / Vacunas contra Papillomavirus / Neoplasias Tipo de estudio: Guideline / Prognostic_studies / Sysrev_observational_studies Aspecto: Implementation_research Límite: Adolescent / Adult / Child / Female / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: CA Cancer J Clin Año: 2020 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos